Amneal Pharmaceuticals Holding Co (AMRX) Cotización

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Represents Amneal’s fourth 505(b)(2) injectable approval in 2024 Ready-to-use oncology treatment used for multiple myeloma and mantle cell lymphoma Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX...

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More

UBS Group AG (NYSE:UBS) – UBS reported a net profit of $1.136 billion in Q2, exceeding the $528 million forecast. Revenue also surpassed expectations, reaching $11.904 billion. Despite...

Amneal Reports Second Quarter 2024 Financial Results

‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full...

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million people currently...

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals...

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company...

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched...

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Builds on U.S. biosimilar portfolio of seven products with three commercial and four in pipeline 8th biosimilar expands portfolio into allergy treatments, a new therapeutic area Amneal...